Product name

GD2 peptide mimotopes for therapy of and vaccination against tumors

Summary

Decapeptide mimotopes with high affinity to GD2 specific antibody provide a tool for therapy and vaccination against different tumors like melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma of the lung.

Organization name

ipal GmbH

Profile

The glycolipid (disialoganglioside) GD2 is an antigen highly expressed in tumor cells of neuroectodermal origin. Its nature was copied by a peptide-mimotope approach done by calculating docking experiments. In principle these GD2 mimicking peptides, applied by DNA vaccination, elicit an innate immune response thus protecting model animals (mice) from spontaneous liver metastases in contrast to control group.

Efficacy was proven

• in vitro by surface plasmon resonance measurements
• in a CHO-1 cell system and
• in vivo by DNA and peptide vaccination of mice.

Protection comprises

• Sequence of two effective decapeptide mimotopes
• vector construction information and
• pharmaceutical composition.

A European patent application has been filed. Additional information is provided in the attached pdf.

The technology was developed at the Charité (Berlin/Germany) and is offered by IPAL.

Contact

Dr. Christian Wunsch
christian.wunsch(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.                    

 

Description File

 06106_GD52_mimotope_Abstract.pdf

URL

http://www.ipal.de/en/technology_offers/life_sciences/

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney